HMGB1 and hepatocellular carcinoma: In the same context, evidence revealed that HMGB1 inhibitors play a significant role in limiting the chemoresistance of hepatocellular carcinoma (HCC) cells to DOX, resulting in the re-sensitization of DOX-treated HCC cells [45].